Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLOV Stock Forecast 2025-2026
$3.28
Current Price
$1.70B
Market Cap
Buy 2
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to CLOV Price Targets
+82.9%
To High Target of $6.00
+37.2%
To Median Target of $4.50
+14.3%
To Low Target of $3.75
CLOV Price Momentum
-7.6%
1 Week Change
-5.2%
1 Month Change
+231.3%
1 Year Change
+4.1%
Year-to-Date Change
-32.6%
From 52W High of $4.87
+264.4%
From 52W Low of $0.90
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Clover Health (CLOV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CLOV and similar high-potential opportunities.
Latest CLOV Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, CLOV has a neutral consensus with a median price target of $4.50 (ranging from $3.75 to $6.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $3.28, the median forecast implies a 37.2% upside. This outlook is supported by 2 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Hewitt at Craig-Hallum, projecting a 82.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLOV Analyst Ratings
2
Buy
2
Hold
0
Sell
CLOV Price Target Range
Low
$3.75
Average
$4.50
High
$6.00
Current: $3.28
Latest CLOV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLOV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 3, 2025 | Canaccord Genuity | Richard Close | Buy | Maintains | $4.50 |
| Dec 17, 2024 | Craig-Hallum | Matt Hewitt | Buy | Initiates | $6.00 |
| Oct 7, 2024 | UBS | Jonathan Yong | Neutral | Initiates | $4.00 |
| Aug 11, 2023 | Citigroup | Jason Cassorla | Neutral | Maintains | $1.50 |
| Mar 6, 2023 | Canaccord Genuity | Richard Close | Buy | Maintains | $3.00 |
| Mar 6, 2023 | Credit Suisse | Jonathan Yong | Underperform | Maintains | $1.25 |
| Nov 16, 2022 | Citigroup | Jason Cassorla | Neutral | Maintains | $1.80 |
| Nov 8, 2022 | SVB Leerink | Whit Mayo | Market Perform | Maintains | $1.50 |
| Aug 9, 2022 | Citigroup | Jason Cassorla | Neutral | Maintains | $3.50 |
| Aug 9, 2022 | Credit Suisse | Jonathan Yong | Underperform | Maintains | $3.00 |
| May 10, 2022 | SVB Leerink | Whit Mayo | Market Perform | Maintains | $3.00 |
| Feb 25, 2022 | SVB Leerink | Whit Mayo | Market Perform | Maintains | $2.50 |
| Feb 2, 2022 | Cowen & Co. | Gary Taylor | Market Perform | Upgrade | $3.00 |
| Feb 2, 2022 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Jan 19, 2022 | SVB Leerink | Market Perform | Initiates | $0.00 | |
| Jan 7, 2022 | Credit Suisse | Underperform | Downgrade | $3.50 | |
| Nov 15, 2021 | Credit Suisse | Jonathan Yon | Neutral | Maintains | $9.00 |
| Sep 10, 2021 | Cowen & Co. | Underperform | Initiates | $0.00 | |
| Jul 12, 2021 | JP Morgan | Underweight | Downgrade | $0.00 | |
| Jun 10, 2021 | B of A Securities | Underperform | Downgrade | $0.00 |
Clover Health Investments Corp. (CLOV) Competitors
The following stocks are similar to Clover Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CLOV
Clover Health
mkt cap
1.77B
Clover Health Investments Corp. (CLOV) Financial Data
Clover Health Investments Corp. has a market capitalization of $1.70B with a P/E ratio of -40.6x. The company generates $1.49B in trailing twelve-month revenue with a -1.7% profit margin.
Revenue growth is +33.4% quarter-over-quarter, while maintaining an operating margin of -0.3% and return on equity of -7.8%.
Valuation Metrics
Market Cap
$1.70B
Enterprise Value
$1.62B
P/E Ratio
-40.6x
PEG Ratio
-23.9x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+33.4%
Gross Margin
+23.6%
Operating Margin
-0.3%
Net Margin
-1.7%
EPS Growth
+33.3%
Financial Health
Cash/Price Ratio
+9.6%
Current Ratio
1.5x
Debt/Equity
0.0x
ROE
-7.8%
ROA
-2.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Clover Health Investments Corp. (CLOV) Business Model
About Clover Health Investments Corp.
What They Do
Next-generation healthcare technology for Medicare Advantage.
Business Model
Clover Health generates revenue by offering Medicare Advantage plans, utilizing its proprietary Clover Assistant software to enhance healthcare delivery. The company focuses on improving patient outcomes and reducing costs through data analytics and personalized care, thus attracting more beneficiaries and healthcare providers.
Additional Information
Clover Health is positioned in the U.S. healthcare sector, emphasizing preventive care and chronic disease management. Its approach aligns with the shift towards value-based care and the growing demand for tech-driven healthcare solutions, making it a noteworthy player in the digital health landscape.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
570
CEO
Mr. Andrew Toy
Country
United States
IPO Year
2021
Website
www.cloverhealth.comClover Health Investments Corp. (CLOV) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
May 15, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
11 days ago
Quick Summary
Clover Health Investments (CLOV) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating growing optimism about its earnings prospects.
Why It Matters
Clover Health's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Clover reported strong Q1 earnings with a 30% YoY member increase. It anticipates $95 million in extra FY 2026 revenue from higher MA payouts and aims for GAAP profitability with a 4-star quality rating.
Why It Matters
Clover's strong Q1 earnings and member growth signal potential revenue increases. Upcoming CMS payouts and a quality bonus could drive profitability, making it an attractive investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
As of May 8, 2025, three health care stocks may signal caution for momentum-focused investors.
Why It Matters
Warning signals in health care stocks indicate potential declines in momentum, which may affect investor confidence and lead to sell-offs or cautious trading strategies.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Clover Health Investments, Corp. will hold its Q1 2025 Earnings Conference Call on May 6, 2025, at 5:00 PM ET, featuring key executives and analysts from various firms.
Why It Matters
Clover Health's upcoming earnings call will provide insights into its financial performance and strategic direction, crucial for evaluating its investment potential and market position.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Clover Health reported Q1 2025 Medicare Advantage membership at 103,418, up 30% YoY. Total revenues reached $462 million, a 33% increase. Adjusted EBITDA rose 279%. Full-year guidance improved, showing strong growth.
Why It Matters
Clover Health's significant membership and revenue growth, coupled with improved profitability metrics, signals strong operational performance and a positive outlook, enhancing investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Clover Health (CLOV) reported Q3 earnings of $0.05 per share, surpassing the Zacks estimate of a $0.07 loss, compared to a loss of $0.05 per share a year prior.
Why It Matters
Clover Health's earnings beat expectations, signaling financial improvement and potential growth, which may boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CLOV Stock
What is Clover Health Investments Corp.'s (CLOV) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Clover Health Investments Corp. (CLOV) has a median price target of $4.50. The highest price target is $6.00 and the lowest is $3.75.
Is CLOV stock a good investment in 2025?
According to current analyst ratings, CLOV has 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLOV stock?
Wall Street analysts predict CLOV stock could reach $4.50 in the next 12 months. This represents a 37.2% increase from the current price of $3.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Clover Health Investments Corp.'s business model?
Clover Health generates revenue by offering Medicare Advantage plans, utilizing its proprietary Clover Assistant software to enhance healthcare delivery. The company focuses on improving patient outcomes and reducing costs through data analytics and personalized care, thus attracting more beneficiaries and healthcare providers.
What is the highest forecasted price for CLOV Clover Health Investments Corp.?
The highest price target for CLOV is $6.00 from Matt Hewitt at Craig-Hallum, which represents a 82.9% increase from the current price of $3.28.
What is the lowest forecasted price for CLOV Clover Health Investments Corp.?
The lowest price target for CLOV is $3.75 from at , which represents a 14.3% increase from the current price of $3.28.
What is the overall CLOV consensus from analysts for Clover Health Investments Corp.?
The overall analyst consensus for CLOV is neutral. Out of 9 Wall Street analysts, 2 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are CLOV stock price projections?
Stock price projections, including those for Clover Health Investments Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 1:33 PM UTC